Jun 01 2018
Auris Health made the coveted CNBC Disruptor 50 List for 2018, making it one of the few healthcare companies to receive the honor. Each year CNBC features private companies of all types whose game-changing innovations are transforming how the world does business. Joining the ranks of Airbnb, Lyft, and SpaceX, Auris was honored for the innovative work it brings to bronchoscopic procedures with its Monarch Platform. The goal of Auris’s robotic technology is to enable more accurate diagnosis, and eventually treatment, of small and hard-to-reach nodules in the periphery of the lung.
Dr. Fred Moll, Auris Health CEO, was featured in CNBC’s in-depth article for the ingenuity he has brought to robotics, including the Monarch Platform. According to the article, Auris’s chief strategy officer Josh DeFonzo explained that "Auris is not out to replace doctors or other clinicians with robots." The article also states that Moll is "willing to build doctors a robot army, if necessary, so that they can treat patients at the best possible levels, consistently."
Excerpts from the article:
“The company aims to help doctors diagnose lung cancer earlier than current technologies and methods, including traditional endoscopes, and needle biopsies. Auris' chief strategy officer, Josh DeFonzo, says that long-term the team also wants to expand beyond diagnostics.”
“I’m a big believer that electromechanical control of medical intervention is the path of the future. But I don’t mean surgery is going to be fully autonomous and we’d replace surgeons. We’re not. Because the most important aspect of surgical technique is judgment, you will always need surgeons. But robotic controls will be able to do more and more.” – Dr. Fred MollRead the Full Article Here